Rosen Law Firm Urges AstraZeneca Investors to Act Before Deadline in Class Action Case

NEW YORK, Jan. 12, 2025 (GLOBE NEWSWIRE) --

IMPORTANT NOTICE: Rosen Law Firm, an established global investor rights law firm, is reaching out to individuals who purchased securities of AstraZeneca PLC (NASDAQ: AZN) during the period from February 23, 2022, to December 17, 2024. Investors are reminded of the upcoming deadline of February 21, 2025, to act as a lead plaintiff in the securities class action lawsuit initiated by the firm.

WHAT THIS MEANS FOR YOU: If you have acquired AstraZeneca securities during the specified period, you might be eligible for compensation without needing to pay out of pocket due to a contingency fee arrangement.

WHAT YOU SHOULD DO: To participate in the AstraZeneca class action, you can visit this link or contact Phillip Kim, Esq. at 866-767-3653 or via email at [email protected] for more details. A class action lawsuit has been filed, and if you aim to be the lead plaintiff, it is crucial to make your move by the deadline of February 21, 2025. The lead plaintiff acts on behalf of other class members in the direction of the legal process.

WHY CHOOSE ROSEN LAW FIRM: Investors are encouraged to opt for experienced legal counsel with a proven success record in considerable roles. Many firms sending out notices may lack the necessary expertise, resources, or peer recognition. Often, these firms merely refer clients or partner with litigating firms rather than representing them directly. Be careful in your choice of legal representation. The Rosen Law Firm serves investors globally, focusing on securities class actions and shareholder derivative litigation. It has a remarkable history of achieving significant settlements, such as securing the largest settlement against a Chinese company and being ranked as the top firm for securities class action settlements by ISS Securities Class Action Services in 2017. For years, it has consistently performed well and recovered substantial amounts for investors, including over $438 million in 2019. In 2020, founding partner Laurence Rosen was acknowledged by Law360 as a Titan of the Plaintiffs' Bar, highlighting the firm's prestige. Additionally, many attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: The lawsuit alleges that the defendants made materially misleading statements or failed to disclose vital information throughout the class period. Specifically, it claims that AstraZeneca was involved in insurance fraud in China, resulting in increased legal risks and the detention of its China president. These revelations could potentially jeopardize AstraZeneca's business operations in China, leading to significant financial consequences for investors.

If you’re interested in joining the AstraZeneca class action, please take action by visiting this link or reaching out to Phillip Kim, Esq. toll-free at 866-767-3653 or by email at [email protected] for more details.

It is essential to note that a class has yet to be certified. Until that occurs, you are not typically represented unless you choose your own counsel. You also have the option to remain an absent class member without taking any action at this stage. Remember, your chance of recovering any potential future compensation does not depend on being a lead plaintiff.

Stay updated with Rosen Law Firm on their LinkedIn, Twitter, and Facebook pages.

Disclaimer: This information is intended for advertisement purposes. Prior results do not guarantee future outcomes.

For inquiries, please contact:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40^th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

AstraZeneca, ClassAction, Investors